Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing and able to provide written consent to participate.
- People who have a recent or archived tissue sample from their tumour available, or who are willing to have a new tissue sample taken.
- People who have been formally diagnosed with one of the following types of mature T-cell or natural killer (NK)-cell lymphoma or leukaemia, confirmed by a pathologist: T-cell prolymphocytic leukaemia; T-cell large granular lymphocytic leukaemia; chronic lymphoproliferative disorder of NK cells; aggressive NK-cell leukaemia; systemic Epstein-Barr virus (EBV)-positive T-cell lymphoma of childhood; chronic active EBV infection of T- and NK-cell type (systemic form); hydroa vacciniforme-like lymphoproliferative disorder; adult T-cell leukaemia/lymphoma; extranodal NK/T-cell lymphoma (nasal type); enteropathy-associated T-cell lymphoma; monomorphic epitheliotropic intestinal T-cell lymphoma; intestinal T-cell lymphoma (not otherwise specified); indolent T-cell lymphoproliferative disorder of the gastrointestinal tract; hepatosplenic T-cell lymphoma; subcutaneous panniculitis-like T-cell lymphoma; mycosis fungoides at stage IB or higher who are currently receiving active treatment; Sézary syndrome; primary cutaneous anaplastic large cell lymphoma in people currently receiving systemic (whole-body) treatment; primary cutaneous gamma-delta T-cell lymphoma; primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma; primary cutaneous acral CD8+ T-cell lymphoma in people currently receiving systemic treatment; peripheral T-cell lymphoma (not otherwise specified); angioimmunoblastic T-cell lymphoma; follicular T-cell lymphoma; nodal peripheral T-cell lymphoma with TFH phenotype; anaplastic large cell lymphoma (ALK-positive); anaplastic large cell lymphoma (ALK-negative); or breast implant-associated anaplastic large cell lymphoma.
Who may not be able to join:
- People diagnosed with mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, or primary cutaneous acral CD8+ T-cell lymphoma who are not currently receiving systemic (whole-body) treatment.
- People for whom the treating doctor determines it would not be possible to collect the necessary ongoing data, assess treatment response, or carry out adequate follow-up during the study.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Steven Horwitz, MD, Memorial Sloan Kettering Cancer Center
Phone: 646-608-2680
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of participants populating the T-cell Lymphoma Master Repository/TCLMR
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.